AURX Stock Overview
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.95 |
| 52 Week High | US$2.95 |
| 52 Week Low | US$0.40 |
| Beta | -678.98 |
| 1 Month Change | 5.57% |
| 3 Month Change | 57.81% |
| 1 Year Change | -67.80% |
| 3 Year Change | 35.71% |
| 5 Year Change | 400.00% |
| Change since IPO | -52.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| AURX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -3.5% |
| 1Y | -67.8% | -1.7% | 20.2% |
Return vs Industry: AURX underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: AURX underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| AURX volatility | |
|---|---|
| AURX Average Weekly Movement | 16.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AURX's share price has been volatile over the past 3 months.
Volatility Over Time: AURX's weekly volatility has decreased from 30% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10 | David Jorden | www.nuot.com |
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014.
Nuo Therapeutics, Inc. Fundamentals Summary
| AURX fundamental statistics | |
|---|---|
| Market cap | US$42.03m |
| Earnings (TTM) | -US$3.48m |
| Revenue (TTM) | US$485.51k |
86.6x
P/S Ratio-12.1x
P/E RatioIs AURX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AURX income statement (TTM) | |
|---|---|
| Revenue | US$485.51k |
| Cost of Revenue | US$97.44k |
| Gross Profit | US$388.07k |
| Other Expenses | US$3.87m |
| Earnings | -US$3.48m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 79.93% |
| Net Profit Margin | -716.32% |
| Debt/Equity Ratio | 0% |
How did AURX perform over the long term?
See historical performance and comparison